GlassScriptPhysician profile
Daniel James Erickson
NPI 1184264327
$1,571.85
in general payments reported to CMS, 2019-2025
17 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.08 · 2023: $466 · 2024: $596 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.17 | 2023-2025 | |
| Novo Nordisk INC | $284.11 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $190.52 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $100.90 | 2024-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $96.93 | 2024-2025 | Veozah |
| Pfizer INC. | $96.48 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $92.07 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $43.78 | 2021-2025 | Trintellix, Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.09 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $23.36 | 2025 | Spravato |
| Exact Sciences Corporation | $23.01 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $19.28 | 2021 | |
| Sanofi Pasteur INC. | $19.22 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.98 | 2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $15.44 | 2023 | Keveyis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.18 | 2023 | Stiolto Respimat, Spiriva Respimat |
| Phathom Pharmaceuticals, INC. | $13.33 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.